Clinical trials: Established Atherosclerotic Cardiovascular Disease
Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in…
- Conditions
- Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
- Trial name
- NCT05355402
- Testing
- Olezarsen
- Where
- 24 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Atherosclerotic Cardiovascular Diseases, Shared-decision Making
Effectiveness of Decision Support for Cardiovascular Risk Management in People With Cardiovascular Disease
This study aims to improve the way patients with cardiovascular diseases are informed about their treatment options. It explores methods to support shared decision-making between patients and doctors.
- Trial name
- 2-DECIDE (NCT06871514)
- Testing
- 2-DECIDE intervention: decision support for cardiovascular risk management, No Intervention: usual care
- Where
- 8 sites in Netherlands
- Volunteers
- 1,200 people
- Sponsor
- dr.Frank L.J. Visseren
Trimethylamine-N-oxide, Gut Microbiota
Red Wine Effects Upon Gut Flora and Plasma Levels of Trimethylamine-N-oxide (TMAO) - WineFlora Study
Recent evidence indicates that Trimethylamine-N-oxide (TMAO) is a pro-atherosclerotic, phosphatidylcholine-dependent metabolite of diet and intestinal flora.
- Conditions
- Trimethylamine-N-oxide, Gut Microbiota, Effects of Red Wine, Atherosclerosis
- Trial name
- NCT03232099
- Testing
- Red Wine consumption, Period without alcohol consumption
- Volunteers
- 42 people
- Sponsor
- University of Sao Paulo General Hospital
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
- Trial name
- NCT06292013
- Testing
- Lepodisiran Sodium
- Where
- 928 sites in United States, Argentina and 26 more
- Volunteers
- 17,300 people
- Sponsor
- Eli Lilly and Company
Peripheral Artery Disease
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
- Trial name
- EUCLID (NCT01732822)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 776 sites in United States, Argentina and 26 more
- Volunteers
- 13,885 people
- Sponsor
- AstraZeneca
Cardiovascular Risk, Obesity
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
This clinical study is being conducted to evaluate the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease (ASCVD) and excess body weight compared with placebo.
- Trial name
- AMBIENCE (NCT07861100)
- Testing
- Zenagamtide
- Where
- 769 sites in United States, Argentina and 24 more
- Volunteers
- 8,500 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Chronic Kidney Disease
The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH
Cardiovascular disease (disease of the heart and blood vessels) is one of the leading causes of death in Canada. It also carries a financial burden on the Canadian economy with a yearly cost close to $21 billion divided between…
- Conditions
- Diabetes, Chronic Kidney Disease, Established Atherosclerotic Vascular Disease, Framingham Risk Score More Than 20 Percent
- Trial name
- RxEACH (NCT01979471)
- Testing
- Advanced Care
- Where
- Canada
- Volunteers
- 723 people
- Sponsor
- University of Alberta
Atherosclerosis
Aliskiren Effect on Aortic Plaque Progression
This study is being done to assess the effectiveness of short term (~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta.
- Trial name
- ALPINE (NCT01417104)
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Ohio State University
Critical Limb Ischaemia, Claudication
Peripheral Vascular Disease and Nerve Stimulation
A study to see what effect the geko™ device has on blood flow in patients with lower limb vascular disease.
- Conditions
- Critical Limb Ischaemia, Claudication, Ulcers, Varicose Veins
- Trial name
- CCLINS (NCT01942941)
- Testing
- geko™ electrical stimulation
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Diabetic Foot, Peripheral Arterial Disease
Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes
In the UK there are over 7,000 leg amputations each year because of diabetes. The most important cause of this is poor circulation. The detection of poor circulation in patients with diabetes is difficult.
- Conditions
- Diabetic Foot, Peripheral Arterial Disease, Diabetic Foot Ulcer, Peripheral Vascular Diseases
- Trial name
- DM PAD (NCT05009602)
- Testing
- Toe Brachial Pressure Index (TBPI), Ankle Brachial Pressure Index (ABPI), Exercise Ankle Brachial Pressure Index (ABPI)
- Where
- 17 sites in United Kingdom
- Volunteers
- 604 people
- Sponsor
- Imperial College London
Atherosclerosis, Cardiovascular Diseases
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease.
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- Trial name
- ACCLAIM-CTA (NCT07613294)
- Testing
- Lepodisiran
- Where
- 58 sites in United States, Australia and 5 more
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
sHTG, HTG With ASCVD (Diagnosed or at Increased Risk)
A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.
This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial evaluating the efficacy and safety of FXR0906 in patients with severe hypertriglyceridemia or hypertriglyceridemia with atherosclerotic…
- Trial name
- NCT07889245
- Testing
- FXR0906 injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
Atherosclerotic Cardiovascular Disease (ASCVD)
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on…
- Trial name
- ADD-VANTAGE (NCT06813911)
- Testing
- Pelacarsen, Inclisiran
- Where
- 94 sites in United States, China and 9 more
- Volunteers
- 246 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerosis
Investigating the Gut Microbiota Modulation Effects of Allicin for Cardiovascular Disease Protection and Establishing Microbiota Directed Personalized Nutrition Guidance With Novel Humanized Gnotobiotic Mice Model, Microbial Culturomics and Metabolomic Technique
Investigators recruited 10 trimethylamine N-oxide (TMAO) producers to test the effect of garlic juice containing allicin on gut microbiota modulation and TMAO production.
- Trial name
- NCT04545879
- Testing
- Raw garlic juice containing allicin
- Where
- Taiwan
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Atherosclerosis
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis
The purpose of this study is to determine the efficacy of treatment with olmesartan medoxomil, an Angiotensin Receptor Blocker, compared to placebo on the blood levels of surrogate markers of vascular inflammation for…
- Trial name
- NCT00382213
- Testing
- Olmesartan medoxomil
- Volunteers
- 210 people
- Sponsor
- Daiichi Sankyo
Atherosclerosis, Cardiovascular Disease
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased…
- Conditions
- Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension
- Trial name
- CLARITY-CRP (NCT07783802)
- Testing
- Clazakizumab
- Where
- 46 sites in United States, Argentina and 2 more
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Atherosclerotic Cardiovascular Disease, Coronary Artery Disease
Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease
Although both enteric-coated and plain formulations of aspirin are being used commonly, there are no high-quality comparisons between these formulations with respect to clinical efficacy outcomes in patients with atherosclerotic…
- Conditions
- Atherosclerotic Cardiovascular Disease, Coronary Artery Disease, Ischemic Heart Disease, Ischemic Stroke
- Trial name
- COATED-AIR (NCT06541691)
- Testing
- Enteric-coated aspirin, Plain aspirin, Hybrid strategy
- Where
- Iran
- Volunteers
- 3,000 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
Atherosclerotic Cardiovascular Disease
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease…
- Trial name
- SIRIUS (NCT05974345)
- Testing
- Inclisiran sodium, Ezetimibe, Evolocumab
- Where
- France
- Volunteers
- 204,691 people
- Sponsor
- Novartis Pharmaceuticals
Colchicine, ICH - Intracerebral Hemorrhage
Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage
Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies.
- Conditions
- Colchicine, ICH - Intracerebral Hemorrhage, Stroke, Dependence
- Trial name
- CoVasc-ICH2 (NCT06587737)
- Testing
- Colchicine 0.5 MG
- Volunteers
- 1,125 people
- Sponsor
- Population Health Research Institute
Cardiovascular Risk, Chronic Kidney Disease
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.
- Conditions
- Cardiovascular Risk, Chronic Kidney Disease, Inflammation
- Trial name
- ZEUS (NCT05021835)
- Testing
- Ziltivekimab B, Ziltivekimab C
- Where
- 1,073 sites in United States, Argentina and 36 more
- Volunteers
- 6,385 people
- Sponsor
- Novo Nordisk A/S